Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk‑Reward Profile?
AtriCure (ATRC) has been added to the Russell 2000 Defensive and Growth-Defensive Indexes, potentially broadening its investor base. This inclusion, along with recent executive share purchases, could influence investor perception, though upcoming Q2 2026 earnings are anticipated to be a more significant factor for the company's financial narrative and future outlook. The article also touches upon competitive pressures and analyst forecasts for the company.
Is AtriCure's (ATRC) Russell 2000 Defensive Debut Quietly Reframing Its Risk‑Reward Profile?
AtriCure (ATRC) has been added to the Russell 2000 Defensive and Growth-Defensive Indexes, potentially broadening its investor base. This comes as company executives increase their holdings through an employee stock purchase plan. While index inclusion and insider purchases are noted, the article emphasizes that the core investment narrative for AtriCure remains its clinical and commercial progress in cardiac surgery devices, with upcoming Q2 2026 earnings being a key near-term milestone.
(ATRC) Movement Within Algorithmic Entry Frameworks
This article analyzes Atricure Inc. (NASDAQ: ATRC) using algorithmic entry frameworks. It highlights a strong near and mid-term sentiment but a weak long-term outlook, with an exceptional risk-reward setup. The analysis provides three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels.
Is AtriCure (ATRC) Still Undervalued Following Its Russell Defensive Index Additions?
AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive Indices after a recent share price rebound. While analysts peg its fair value at $47.00, suggesting undervaluation based on growth assumptions, a discounted cash flow model presents a more conservative valuation of $0.75, indicating potential overvaluation on cash generation. The article advises investors to analyze both perspectives and consider risks before making investment decisions.
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (NASDAQ: ATRC) announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. The company will also host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested parties can register online for the conference call.
AtriCure (ATRC) COO adds ESPP shares in routine acquisition
AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company’s 2018 Employee Stock Purchase Plan. The shares were purchased at $23.78 each, reflecting an 85% discount of the closing price on June 30, 2026, and increased his direct holdings to 229,867 shares. This transaction is considered a routine acquisition with a neutral impact and sentiment.
AtriCure (ATRC) CTO adds shares through discounted Employee Stock Purchase Plan
AtriCure's Chief Technical Officer, Salvatore Privitera, acquired 636 shares of company stock through the 2018 Employee Stock Purchase Plan (ESPP) on June 30, 2026. These shares were purchased at a discounted price of $23.78 each, representing 85% of the closing price of $27.98 on that date. This transaction, classified as a routine compensation-related acquisition rather than an open-market trade, brings his direct holdings to 158,684 shares.
Press Release: AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC) announced it will release its second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update on the same day at 4:30 p.m. ET.
AtriCure to announce second quarter 2026 financial results
AtriCure, Inc. will release its second quarter 2026 financial results on Thursday, July 23, 2026, followed by an audio webcast at 4:30 p.m. Eastern Time. The company specializes in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management. Investors can register online for the webcast, which will provide insights into the company's performance, key financial metrics, and operational updates.
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC) announced it will release its second quarter 2026 financial results on Thursday, July 23, 2026. The company will also host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. AtriCure specializes in surgical treatments for atrial fibrillation, LAA management, and post-operative pain management.
Form 4 AtriCure Inc For: 2 July By Investing.com
This article announces the filing of Form 4 for AtriCure Inc. on July 2nd. It provides key stock market data for various indices, commodities, and individual stocks. The content also includes a list of popular news and analysis articles from Investing.com.
AtriCure (ATRC) CEO adds 636 shares through 2018 Employee Stock Purchase Plan
AtriCure, Inc.'s President and CEO, Michael H. Carrel, acquired 636 shares of common stock at $23.78 per share through the company's 2018 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, increased his direct holdings to 779,134 shares. The shares were purchased at 85% of the closing price on that date, reflecting his continued participation in employee equity programs.
AtriCure, Inc. (ATRC) CSO acquires 636 ESPP shares at discount
AtriCure, Inc.'s Chief Scientific Officer, Doraiswamy Vinayak, acquired 636 shares of common stock through the company's 2018 Employee Stock Purchase Plan. The shares were purchased on June 30, 2026, at a discounted price of $23.78 per share, which is 85% of the closing price of $27.98 on that day. This transaction increased his direct holdings to 92,511 common shares and is considered a routine, compensation-related acquisition rather than an open-market trade.
Canaccord reiterates AtriCure stock Buy rating after FDA clearance
Canaccord Genuity has reiterated its Buy rating and a $55.00 price target for AtriCure Inc. (NASDAQ:ATRC) following FDA clearance for a competing left atrial appendage exclusion system from Edwards Lifesciences. Despite the new competition, Canaccord expects minimal impact on AtriCure's dominant AtriClip business, citing Edwards' focus on the valvular market and Medtronic's previous failure to gain traction with a similar product. The firm projects 13% year-over-year growth for AtriClip in 2026 and notes AtriCure's strong revenue growth and gross profit margin, with analysts predicting profitability for the company this year.
AtriCure (ATRC) Joins Multiple Russell 2000 Defensive Indexes Is Its Risk Profile Evolving?
AtriCure (ATRC) has been added to the Russell 2000 Growth-Defensive and Defensive indexes, which could boost its visibility and liquidity. While this inclusion may attract investment, the fundamental risks and opportunities related to its product pipeline and competition, particularly from PFA, remain key drivers for its long-term financial performance. The article suggests investors examine future revenue and earnings forecasts closely in light of these developments.
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences has received FDA clearance for its Ecliptis left atrial appendage exclusion system, positioning it to compete with AtriCure's AtriClip and Medtronic's Penditure system. The device aims to prevent stroke in atrial fibrillation patients by closing the LAA. Edwards plans a targeted rollout, leveraging its existing surgical valve infrastructure.
AtriCure, Inc. Actuals & Estimates (NASDAQ:ATRC)
This article provides an overview of AtriCure, Inc. (NASDAQ: ATRC) stock, including its current price of $30.18, market capitalization of $1.42 billion, and recent performance. It details analyst forecasts, with a maximum estimate of $55.00 and a minimum of $36.00, and mentions key financial data such as revenue and net income. The company's next earnings report is scheduled for August 4, 2026.
ATRC Forecast — Price Target — Prediction for 2027
The article provides an overview of AtriCure, Inc. (ATRC) stock, including its current price, analyst forecasts, and historical performance. It details financial metrics such as revenue, net income, and market capitalization, along with upcoming earnings dates. The content also addresses frequently asked questions about ATRC's stock, aiding potential investors in their research.
AtriCure, Inc. Actuals & Estimates (DUS:A5I)
This article provides financial actuals and estimates for AtriCure, Inc. (DUS:A5I), including its stock ticker, analyst forecast, historical prices, revenue, net income, and EBITDA. It also notes that the company does not pay dividends and details its next earnings report date.
AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for AtriCure Inc (ATRC), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 6.67, ranking 52 out of 204 in the Healthcare Equipment & Supplies industry, and a beta of 1.27, indicating higher volatility compared to the S&P 500. Various metrics including beta, VaR, maximum drawdown, volatility, return, Sharpe Ratio, skewness, and liquidity are presented to illustrate the stock's risk profile.
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) stock is currently trading around $28.80, with one narrative suggesting it is 45.4% undervalued with a fair value of $52.78, based on strong growth assumptions from its innovative medical devices. However, a discounted cash flow (DCF) model presents a contrasting view, valuing the stock at approximately $1.69, indicating it might be overvalued. This article highlights the tension between growth expectations and cash flow realities, urging investors to consider both perspectives and associated risks before making investment decisions.
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) stock is currently trading around $28.80, with one narrative suggesting it is 45.4% undervalued at a fair value of $52.78, driven by projected rapid revenue growth and rising margins. However, another analysis using a Discounted Cash Flow (DCF) model indicates the stock is overvalued, with an estimated future cash flow value of about $1.69. This creates a tension for investors between an optimistic growth-based valuation and a more conservative cash flow-based assessment.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) shares rose 6.2% after a presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated a goal of $1 billion in revenue by 2030 and highlighted market expansion potential from clinical trials. Despite the surge, the stock holds a Zacks Rank #3 (Hold) due to unchanged consensus EPS estimates, prompting investors to monitor future estimate revisions for sustained growth. QuidelOrtho (QDEL), another stock in the same industry, also saw a 4.1% increase.
AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis
AtriCure Inc (ATRC) currently holds a robust financial score of 7.37, ranking 81st in the Healthcare Equipment & Supplies industry. The company reported a significant quarterly revenue increase of 14.26% year-over-year, reaching $141.25 million, and a net profit increase of 101.60% year-over-year. Despite strong operational efficiency and growth potential, detailed figures for key financial metrics such as cash and cash equivalents, total assets, and operating profit are not yet disclosed by the company.
AtriCure Inc (ATRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of AtriCure Inc (ATRC), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that ATRC is trading between a resistance level of $30.29 and a support level of $26.34, suggesting potential for range-bound swing trading. The analysis also includes a summary of various technical indicators and moving averages, which collectively suggest a "Buy" signal for the stock based on current readings.
AtriCure Inc (ATRC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for AtriCure Inc (ATRC), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 10 analysts, the stock has a "Buy" trend with an average target price of $50.00 and an expected revenue of $152.05M for the next quarter.
AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure and institutional holdings of AtriCure Inc (ATRC). It lists the major shareholders, their proportion of holdings, and categorizes shareholders by type. The report also provides a historical overview of institutional shareholding data and details recent shareholder activity of key institutions.
AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a detailed breakdown of AtriCure Inc.'s (ATRC) revenue by business segments and geographical regions, with data updated as of April 6. For Fiscal Year 2025, revenue is categorized into areas like Appendage Management, Open Ablation, and Pain Management, both within the United States and internationally. Regionally, the United States accounts for the majority of the company's revenue, followed by Europe and Asia.
AtriCure Inc (ATRC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of AtriCure Inc's (ATRC) dividend distribution and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock price information and market capitalization for ATRC.
Trading Systems Reacting to (ATRC) Volatility
This article from Stock Traders Daily discusses the volatility of Atricure Inc. (NASDAQ: ATRC), highlighting a potential near-term shift in sentiment and a mid-channel oscillation pattern. It presents an exceptional short setup with a high risk-reward ratio and outlines three distinct AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) for various risk profiles. The analysis includes multi-timeframe signals, identifying support and resistance levels.
Do Options Traders Know Something About AtriCure Stock We Don't?
Options traders are showing significant interest in AtriCure (ATRC) stock, with the July 17, 2026 $17.50 Call exhibiting high implied volatility. While this suggests expectations of a big price move, analysts currently rate AtriCure as a Zacks Rank #3 (Hold) with recent downward revisions to earnings estimates. This situation may indicate an opportunity for options traders to sell premium, betting that the stock's movement will be less volatile than implied.
Do Options Traders Know Something About AtriCure Stock We Don't?
Options traders are showing significant interest in AtriCure (ATRC), with the July 17, 2026 $17.50 Call exhibiting high implied volatility, suggesting expectations of a substantial price movement. Despite this, analysts have a "Hold" rating on the stock, revising earnings estimates downwards, which indicates a potential discrepancy between options market sentiment and fundamental outlook. This scenario might attract seasoned options traders looking to sell premium.
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Enrollment Finishes A Year Early
AtriCure (ATRC) has gained attention after its BoxX-NoAF clinical trial enrollment completed a year early, despite its share price falling 31.46% year to date. The stock is considered 49% undervalued by a popular narrative, with a fair value of $52.78 against a current price of $26.92, largely due to expected revenue growth and future profitability from expanded market indications. However, Simply Wall St's DCF model suggests a much lower intrinsic value of $1.69 per share, indicating a significant discrepancy in valuation methods.
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Enrollment Finishes A Year Early
AtriCure (ATRC) has gained attention after its BoxX-NoAF clinical trial completed patient enrollment a year early, despite the stock being down 31.46% year-to-date. While analysts see the stock as undervalued with a fair value of $52.78, Simply Wall St's DCF model suggests a much lower cash-flow-
AtriCure (ATRC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
AtriCure presented at the Goldman Sachs 47th Annual Global Healthcare Conference, outlining a strategic vision to reach $1 billion in revenue by 2030, driven by double-digit growth in arrhythmia and pain management. The company emphasized its dominant market share, aggressive R&D investment, and key clinical trials like BoxX-NoAF and LeAAPS which are expected to significantly expand its addressable market. AtriCure highlighted its competitive moat through continuous innovation, strong clinical data, and long-standing customer relationships.
How Investors May Respond To AtriCure (ATRC) Accelerating BoxX-NoAF Trial Enrollment And Q1 2026 Momentum
AtriCure (ATRC) recently announced strong Q1 2026 earnings and revealed that its BoxX-NoAF atrial fibrillation trial is 12 months ahead of schedule, with enrollment expected to finish by the end of 2026. This accelerated timeline, combined with momentum in its pain management segment, could influence investor sentiment by sharpening clinical catalysts but also heightening execution risks related to trial outcomes and R&D spending. While some analysts have already projected optimistic revenue and earnings for AtriCure by 2029, the faster BoxX-NoAF timeline could either reinforce this positive outlook or challenge it if rising trial costs become less manageable.
How Investors May Respond To AtriCure (ATRC) Accelerating BoxX-NoAF Trial Enrollment And Q1 2026 Momentum
AtriCure (ATRC) reported strong Q1 2026 earnings and announced its BoxX-NoAF atrial fibrillation trial is 12 months ahead of schedule, with enrollment expected by late 2026. This accelerated timeline could both strengthen the investment narrative by bringing clinical catalysts forward and heighten risks related to trial outcomes and increased R&D spending. While a faster timeline seems positive, investors should consider the potential for rising trial costs and concentrated product risk impacting AtriCure's profitable revenue growth by 2028.
AtriCure faces market doubts despite revenue growth; share prices fall. Insider optimism hints at potential turnaround, but long-term earnings are the focus.
AtriCure (NASDAQ: ATRC) has seen its share price drop by 8.2% this week, contributing to a 48% loss over the past three years, despite revenue growth. The article suggests that while market doubts persist, insider optimism hints at a potential turnaround. The primary focus for the company remains on long-term earnings to address shareholder concerns.
AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule
AtriCure, Inc. (ATRC) has announced that its BoxX-NoAF clinical trial for atrial fibrillation treatment is advancing 12 months ahead of schedule, with patient enrollment expected to conclude by the end of 2026 and trial results potentially available in 2027. This development follows strong Q1 2026 earnings, which saw a 14.3% year-over-year revenue jump, exceeding analyst expectations, primarily driven by its pain management segment. Needham reiterated a Buy rating and a $45 price target, highlighting the accelerated trial timeline as a significant catalyst for unlocking new market opportunities.
AtriCure, Inc. Hits 52-Week Low at USD 25.37 Amid Market Struggles
AtriCure, Inc. (Pharmaceuticals & Biotechnology sector) has recently hit a new 52-week low of USD 25.37, down from its 52-week high of USD 43.18, amidst significant stock volatility. Despite a one-year performance of 18.35%, it significantly lags behind the S&P 500's 28.2% performance. The company, with a market capitalization of USD 1,516 million, is currently loss-making with a negative return on equity and does not offer dividends, highlighting financial challenges.
AtriCure stock hits 52-week low at 25.51 USD By Investing.com
AtriCure Inc. stock has reached a new 52-week low of $25.39, trading just above its 52-week low of $25.52. Despite a 22% decline over the past year and 33% year-to-date, InvestingPro analysis suggests future profitability with analysts predicting profitability this year and revenue growth to $552 million, indicating the stock is currently undervalued. Needham recently reiterated a Buy rating and a $45.00 price target following strong Q1 2026 financial results, which showed revenue exceeding expectations and increased profitability.
AtriCure stock hits 52-week low at 25.51 USD By Investing.com
AtriCure Inc. (ATRC) stock has fallen to a new 52-week low of $25.39, representing a 22% decline over the past year and 33% year-to-date. Despite the downturn, analysts predict the medical device company will achieve profitability this year with revenue growing to $552 million, and InvestingPro indicates the stock is undervalued with price targets significantly above current levels. The company recently reported strong Q1 2026 financial results with notable revenue growth, leading Needham to reiterate its "Buy" rating.
AtriCure stock hits 52-week low at 25.51 USD By Investing.com
AtriCure Inc. (ATRC) stock hit a new 52-week low of $25.39, marking a significant decline of 22% over the past year and 33% year-to-date. Despite recent challenges, analysts predict profitability for the medical device company this year, with expected revenue growth of 15% to $552 million. InvestingPro suggests the stock is currently undervalued, with price targets ranging from $36 to $55, indicating substantial upside potential.
Top 10 Small Cap Stocks With Huge Growth Potential
This article highlights AtriCure, Inc. (NASDAQ: ATRC) as a top small-cap stock with significant growth potential. The medical device company recently exceeded Q1 2026 earnings estimates, reporting a 14.3% year-over-year revenue increase driven by its pain management segment. A key development is the accelerated timeline for the BoxX-NoAF clinical trial, with patient enrollment expected to conclude by the end of this year, potentially opening a major new market opportunity by 2027.
AtriCure stock hits 52-week low at 25.51 USD
AtriCure Inc. (ATRC) stock has reached a new 52-week low at $25.39, reflecting a significant year-over-year and year-to-date decline. Despite past unprofitability and current challenges, InvestingPro analysis and recent strong Q1 2026 financial results, which exceeded revenue expectations, suggest a potential turnaround, with analysts predicting profitability and substantial revenue growth this year, and Needham maintaining a "Buy" rating.
Top 10 Small Cap Stocks With Huge Growth Potential
This article highlights AtriCure, Inc. (NASDAQ:ATRC) as a top small-cap stock with significant growth potential, detailing its strong Q1 2026 earnings and an accelerated timeline for its BoxX-NoAF clinical trial. The company's focus on atrial fibrillation treatment devices and positive data readouts from its trials are expected to unlock major market opportunities. Needham reiterated its "Buy" rating and $45 price target, citing the company's strong performance and clinical trial progress.
AtriCure (Nasdaq:ATRC) - Stock Analysis
This stock analysis for AtriCure (Nasdaq:ATRC) highlights the company's valuation as 46.4% undervalued by analysts, with earnings projected to grow 51.41% annually. Despite positive Q1 2026 growth and profitability, the stock faces competitive concerns, particularly from Edwards Lifesciences. Recent news also covers the company's new product launches, clinical trial progress like BoxX-NoAF and LeAAPS, and ongoing analyst revisions to price targets based on both strong performance and emerging competitive risks.
AtriCure director Karen Prange sells $85,950 in company stock
AtriCure director Karen Prange sold 3,000 shares of company stock for a total of $85,950 on May 20, 2026. This transaction leaves Ms. Prange with 26,373 shares. Despite a year-to-date stock decline, InvestingPro analysis suggests the stock is undervalued and analysts predict profitability for the company this year.
(ATRC) and the Role of Price-Sensitive Allocations
Atricure Inc. (NASDAQ: ATRC) shows strong near-term sentiment with neutral mid and long-term outlooks, featuring a mid-channel oscillation pattern. AI models suggest specific institutional trading strategies, including long, breakout, and short positions, with an exceptional 65.4:1 risk-reward setup targeting a 19.5% gain versus 0.3% risk. The analysis provides multi-timeframe signal insights, including support and resistance levels for various holding periods.
AtriCure director Karen Prange sells $85,950 in company stock
AtriCure director Karen Prange sold 3,000 shares of the company's common stock for $85,950 on May 20, 2026, reducing her direct ownership to 26,373 shares. This insider sale comes as AtriCure's stock is down 27% year-to-date, despite the company reporting strong Q1 2026 financial results with increased revenue and reiterated guidance. Needham maintained a Buy rating on ATRC with a $45.00 price target, reflecting confidence in its strategic direction.
